ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin

Summary

The goal of this clinical research study is to learn if the drug ZD1839 (Iressa) can shrink or slow the growth of cancer in participants with recurrent and/or metastatic squamous cell cancer (SCC) of the skin. The safety of this drug will also be studied.

Timeline

Start

2004-05

Primary completion

2012-10

Completion

2012-10

Drugs

Indications